Date: 23-Jun-2020

Neurocline Biosciences And Takeda Announce Collaboration To Develop And Commercialize Drug Candidates For Mental Illness

Neurocline Biosciences and Takeda Pharmaceutical Co., Ltd. announced a strategic collaboration to develop and commercialize compounds in the early to mid-stage development of Takeda's pipeline for mental illness. Specifically, Takeda has monopolized Neurocline Biosciences for seven pipeline programs, including three clinical-stage assets targeting schizophrenia, treatment-resistant depression and anhedonia. License is granted.

Dr. Kevin Gorman, CEO of Neurocline Biosciences, said: “We can work with Takeda to deliver life-changing treatments to people with severe, difficult and under-treated mental illness who need better treatment options. We are very pleased to say that with our deep knowledge in the fields of psychiatry and neurology, we are developing new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline. We look forward to developing, and this strategic alliance will strengthen our growing pipeline and strengthen our position as a leading biopharmaceutical company focused on neuroscience.”

Sarah Sheikh (MD, M.Sc., MRCP), Head of Neuroscience Therapeutics Division, Takeda Pharmaceutical Co. Ltd., said: ``Neurocline Biosciences has many years of experience in the development and commercialization of therapeutic agents for severe neuropsychiatric disorders, and we continue to develop our mental illness portfolio in the early to mid-stage of development. We are an ideal partner in delivering new therapeutic drugs that can be produced to patients.Takeda is deeply committed to neuroscience as one of our core therapeutic areas. Through a strategic alliance with Klein Biosciences, we continue to strengthen our position as a leader in the psychiatric field, and our assets are in the clinical stage for rare neurological diseases such as narcolepsy, developmental epileptic encephalopathy and neurodegenerative diseases. As we move forward, we can deliver therapeutic drugs to target patients in the future.”